DBV Technologies
Clinical trials sponsored by DBV Technologies, explained in plain language.
A biopharmaceutical company focused on food allergy treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Peanut patch for toddlers: could a sticker ease allergy fears? Results expected Nov 2026 (estimated) 🚀 Make-or-break
-
Peanut patch for toddlers: could a sticker ease allergy fears?
Disease control OngoingThis study is testing a skin patch called Viaskin that delivers a tiny amount of peanut protein to help 1-3 year olds with peanut allergy. The goal is to see if the patch is safe over 6 months. About 480 children will wear the patch or a placebo daily. This is a phase 3 trial, me…
Phase 3 • Sponsor: DBV Technologies • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Peanut patch could let allergic kids tolerate small amounts of peanut
Disease control OngoingThis study tests a daily skin patch called DBV712 (Viaskin Peanut) in 600 children aged 4-7 with peanut allergy. The patch delivers a tiny amount of peanut protein to train the immune system to be less sensitive. After 12 months, researchers check if children can safely eat more …
Phase 3 • Sponsor: DBV Technologies • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC